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Recently several reports have demonstrated that innate immune response and
inflammation have an important role in major neurodegenerative diseases. The activation
of the NF-κB family of transcription factors is a key step in the regulation of pro
inflammatory cytokine expression. Microglia and other cell types in the brain can be
activated in response to endogenous danger molecules as well as aggregated proteins
and brain injury. During the past couple of years several studies reported the role
of cystatins in neuroinflammation and neurodegeneration. In the present review, I will
summarize and analyze recent findings regarding the role of cystatins in inflammation
and NF-κB activation. Type I cystatin stefin B (cystatin B) is an endogenous cysteine
cathepsin inhibitor localized in the cytosol, mitochondria and nucleus. Mutations in the
gene of stefin B are associated with the neurodegenerative disease known as Unverricht-
Lundborg disease and microglial activation plays an important role in the pathogenesis
of the disease. Stefin B deficient mice have increased caspase-11 expression and
secreted higher amounts of pro-inflammatory cytokines. The increased caspase-11 gene
expression, was a consequence of increased NF-κB activation.
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INTRODUCTION
The innate immune response represents not only the first line of defense against invading
microorganisms, but also responds to endogenous stress and has a crucial role in the pathology
of neurodegenerative diseases in the central nervous system (CNS). It is elicited through the
detection of pathogen-associated molecular patterns (PAMPs) and danger-associated molecular
patterns DAMPS (Akira et al., 2006; Medzhitov, 2007). In the CNS, pattern-recognition receptors
(PRRs) are primarily expressed by microglia and astrocytes. DAMPs are endogenous molecules,
released by dying or damaged cells after cellular stress and can be recognized by PRRs such
as membrane-bound toll-like receptors (TLRs) or cytosolic nucleotide-binding domain and
leucine-rich repeat-containing (NLR), the RIG-I-like receptor (RLR), the AIM2-like receptor
(ALR; Medzhitov, 2007; Moresco et al., 2011; Franchi et al., 2012). Triggering of PRRs by PAMPs
or DAMPs results in signaling pathways that promote gene transcription by nuclear factor-κB
(NF-κB) as well as interferon regulatory factors (IRFs) and leads to production of interferons
and pro-inflammatory cytokines (Akira et al., 2006; Kawai and Akira, 2009). TLR4 and the
extracellular adaptor protein MD-2 form a lipopolysacharide (LPS) receptor complex. Upon
LPS binding and receptor homodimerization, the signal transducing adapter proteins become
associated with the receptor and trigger the signaling pathway resulting in the activation of
the nuclear NF-κB (Visintin et al., 2003; Medzhitov, 2007). With the exception of TLR3, TLRs
and the IL-1R family use the adaptor MyD88 for signal transduction, which recruits the kinases
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IRAK1 and IRAK4 as well as TRAF6 through its death domain
(Muzio et al., 1997; Wesche et al., 1997; Kobayashi et al., 2002).
The result of these sequential steps is the activation of inhibitors
of NF-κB kinase (IKK) complex and the transcription factor
nuclear factor kappa B (NF-κB). Viral PAMPs, like nucleic acids
are recognized by endosomal TLRs −3, −7, −8 and −9, as well
as by RLRs. Triggering endosomal TLRs by viral PAMPs leads to
the activation of NF-κB and IRFs, which cooperatively mediate
the production of IFN-α/β (Apostolou and Thanos, 2008). In the
CNS, pattern-recognition receptors are primarily expressed by
microglia, macrophages and astrocytes.
A crucial component of the innate immune response
is the inflammasome, a NLR-based multiprotein complex
responsible for the activation of caspase-1 (Martinon and
Tschopp, 2007; Latz et al., 2013; Lamkanfi and Dixit, 2014).
Members of the NLR family (NLR proteins –NLRP) and the
adaptor ASC form multiprotein complexes which are required
for the activation of the pro-inflammatory caspase-1 and
subsequent processing of pro-interleukin (IL)-1β and pro-IL-
18 into the mature forms that are released from the cell
(Martinon and Tschopp, 2007; Takeuchi and Akira, 2010).
The inflammasome activation should be tightly regulated in
order to protect the host and limit the excessive inflammation.
Recently, several excellent reviews described mechanism of
inflammasome activation (Lamkanfi and Dixit, 2014; Guo et al.,
2015). Particullary the activation of NLRP3 inflamamsome
is well characterized (Martinon and Tschopp, 2007; Jabaut
et al., 2013; Latz et al., 2013). The nucleotide binding and
oligomerization domain-like receptor family pyrin domain
containing 3 (NLRP3) inflammasome, is composed of NLRP3,
the adaptor molecule apoptosis-associated speck-like protein
which contain a caspase recruitment domain (ASC) and the
cysteine protease caspase-1. The first, priming step is provided
by TLR signaling that up-regulates NLPR3 and pro-IL-1β
gene expression. This process is tightly controlled by signals
culminating in the activation of NF-κB (Bauernfeind et al.,
2009).
Recently not only canonical NLRP3 inflammasome activation
(LPS and ATP), but also non-canonical inflammasome activation
was reported (Kayagaki et al., 2011; Rathinam et al., 2012;
Broz and Monack, 2013). Canonical inflammasomes activation
results in procaspase-1 cleavage and activation, whereas the
activation of a noncanonical inflammasome results in activation
of procaspase-11 (Lamkanfi and Dixit, 2014). The canonical
and noncanonical inflammasomes regulate release of IL-1α and
IL-1β (Kayagaki et al., 2011). Both proinflamatory caspases-1
and -11 could induce pyroptosis, however only caspase-1
processes proforms of cytokines IL-1β and IL-18 into active
forms which are secreted (Kayagaki et al., 2011). Recently
two independent reports demonstrated that gasdermin D, a
substate for caspase-11, was essential for caspase-11-dependent
pyroptosis and interleukin-1β maturation (Kayagaki et al.,
2015; Shi et al., 2015). Caspase-11 responds to cytoplasmic
LPS independent of Toll-like receptor 4 (Hagar et al., 2013;
Kayagaki et al., 2013). The mouse caspase-11 has high similarities
to caspase-1 and is orthologous to human caspases-4 and
-5 (Wang et al., 1996; Kajiwara et al., 2014). Interestingly,
caspase-11-deficient mice, but not caspase-1-deficient mice are
partially protected from septic death (Wang et al., 1998; Kayagaki
et al., 2011).
In neurons NLRP1 and Aim2 inflammasomes were described
(de Rivero Vaccari et al., 2009; Adamczak et al., 2014)
and in microglia microglia NLRP3 (Halle et al., 2008),
NLRP2 inflammasome was reported in human astrocytes
(Minkiewicz et al., 2013). Recent study by Adamczak et al.
(2014) reported that activation of the Aim2 inflammasome
in neurons by cerebrospinal fluid from traumatic brain
injury patients resulted in neuronal pyroptosis. Recently,
several reviews described the role of innate immune response
and inflammasome activation in neurodegenerative diseases
(Heneka et al., 2014, 2015; Freeman and Ting, 2015). The
CNS is particularly sensitive to IL-1β and IL-18 signaling
because several cell types in the CNS express receptors for
these cytokines (Allan et al., 2005; Alboni et al., 2010).
Recently, several reviews described the role of innate immune
response and inflammasome activation in neurodegenerative
diseases (Heneka et al., 2014, 2015; Freeman and Ting,
2015).
MICROGLIA AND ASTROCYTES—IMMUNE
CELLS IN THE BRAIN
In CNS, the blood-brain barrier (BBB) limits entry of
peripherally derived innate and adaptive immune cells and
their associated inflammatory molecule and plasma proteins
(Banerjee and Bhat, 2007). Moreover, the CNS environment
is anti-inflammatory, featuring high local concentrations of
inflammation-suppressive cytokines such as TGF-β and IL-10
(Zocchia et al., 1997). Microglia are CNS-resident myeloid cells
of embryonic hemeatopoietic origin and represent a major
cellular component of the innate immune system in CNS (Aguzzi
et al., 2013). Similar to tissue macrophages, microglia survey
the brain for pathogens and support CNS homeostasis and
plasticity; by guarding and remodeling synapses (Wake et al.,
2009; Parkhurst et al., 2013). Other cell types in the brain,
endothelial cells, astrocytes, and neurons, can also contribute
to inflammatory responses in the brain. They also express
innate immune receptors and can directly respond to DAMPs
or PAMPs. In a resting state microglia cells have a ramified
morphology, they have a large number of processes that
enable the interaction of microglia with neurons and astrocytes.
They search for dysfunctional synapses, which they are able
to eliminate by phagocytosis (Wake et al., 2009; Tremblay
et al., 2010). After immunological stimuli, like viral infection or
brain injury microglia cells are activated (Davalos et al., 2005;
Nimmerjahn et al., 2005) and acquire a compact phenotype.
They upregulate several surface receptors, like receptors for
neuro-transmitters, cytokines and chemokines, as well as PRRs
(Rock et al., 2004; Block et al., 2007). Several TLRs are
expressed on microglial surface, including TLR2, TLR4 and TLR6
(Udan et al., 2008; Stewart et al., 2010; Fellner et al., 2013).
Activation of TLR4 together with CD14 is implicated in brain
inflammation and microglial activation in response to sepsis
(Chakravarty and Herkenham, 2005). The activation of microglia
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FIGURE 1 | Innate receptor signaling and stefin B influence NF-κB activation and caspase-11 expression in macrophages. Stefin B could act an inhibitor
of cysteine cathepsins in cytosol (1) and nucleus (2) in mitochondria (3) prevents the excessive ROS formation. Toll-like receptor (TLR) signaling is activated by TLR
ligands. Signaling through TLR4 which is located in plasma membrane activate NF-κB via MyD88 dependent pathway. Moreover, caspase-11 expression is regulated
by NF-κB signaling. In addition, LPS stimulation results in increased mitochondrial ROS formation. LPS stimulation could lead to non-canonical inflammasome
activation of caspase-11 and caspase-1 that results in IL-1β and IL-18 processing and secretion.
also leads to production of reactive oxygen species (ROS)
through the induction or activation of NADPH (Shimohama
et al., 2000) and NO (Vodovotz et al., 1996; Heneka et al.,
2001).
Astrocytes provide neuronal support in healthy conditions
and can undergo several phenotypic changes that could be
protective or causative with regard to pathology (Sofroniew
and Vinters, 2010). For the difference from microglia astrocytes
descend from neuroepithelial stem cells. Upon triggering of
TLR, astrocytes participate in innate immune reactions and
secrete inflammatory mediators, like complement components,
IL-1β and IL-6. It was reported that astrocyte exposure to
LPS switches astrocyte of pro-inflammatory genes expression
(Hamby et al., 2012; Zamanian et al., 2012). Interestingly, the
ischemeia caused by experimental stroke in vivo shifts the
astrocyte transcriptome towards neuroprotective mechanisms
(Zamanian et al., 2012). Although astrocytes may undergo
distinct phenotypic changes and secrete pro-inflammatory
cytokines, recent study demonstrated that NLRP3 inflammasome
was not functional in mouse astrocytes, but only in microglia cells
(Gustin et al., 2015). However, it was reported that in human
astrocytes NLRP2 inflammasome was activated by the ATP and
the procersing of caspase 1 and IL-1βwas confirmed (Minkiewicz
et al., 2013). Activation of innate immune receptors, as well
as inflammasome activationa and IL-1β release activate NF-κB
signaling.
NF-κB
Nuclear factor kappa B (NF-κB) was first described by David
Baltimore, as an inducible transcription factor in lymphocytes
(Sen and Baltimore, 1986). In the CNS, NF-κB signaling is
essential in several of physiological as well as pathological
processes associated with neurodegeneration (Kaltschmidt et al.,
1997; Ghosh et al., 2007; Crampton and O’Keeffe, 2013).
The NF-κB family comprises several transcription factors that
contain Rel-homology domains (RHDs) that bind to specific
DNA sequences known as κB sites present in promoter and
enhancer regions of various genes (Hayden and Ghosh, 2012).
In mammalian cells five NF-κB factors were described: RelA
(p65), RelB, c-Rel, p105 (NF-κB1; a precursor of p50) and p100
(NF-κB2; a precursor of p52; May and Ghosh, 1997). Homo-
and heterodimers dimers could be formed through N-terminal
DNA-binding/dimerization domain, known as the Rel homology
domain. NF-κB dimers can modulate gene expression by
binding to a variety of DNA sequences called κB sites (Karin,
2009). RelB, c-Rel, and p65 contain C-terminal transcription
activation domains that enable recruitment of co-activator and
target gene expression. p50 and p52 could form heterodimers
with p65, c-Rel, or RelB and activate transcription of target
genes. In addition, when they form homodimers, they repress
transcription on binding to DNA (Hayden and Ghosh, 2011).
In resting cells, NF-κB complexes are inactive, located mainly
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in the cytoplasm in a complex with IκB proteins. The IκB
inhibitors contain ankyrin repeats and seven different inhibitors
were described: IκBα, IκBβ, IκBε, IκBζ, p100, p105, Bcl3, IκBns.
IκBα, IκBβ, IκBγ and IκBε can hide the nuclear localization
signal of NF-κB in the cytoplasm by direct interactions and
this way prevent nuclear translocation of NF-κB. On the
other hand, Bcl-3, IκBζ and IκBNS are present in the nucleus
and interact with NF-κB to regulate transcription (Hayden
and Ghosh, 2008; Karin, 2009). Upon activation of innate
receptors and signaling the rapid phosphorylation of specific
serine residues of IκB proteins by a multiprotein complex
termed the IKK complex occurs. IKK complex consists of two
catalytically active kinases, IKKα and IKKβ, and a regulatory
protein NEMO (NF-κB essential modifier, also known as IKKγ).
IKKα and IKKβ are structurally similar and have a kinase
domain, a leucine zipper domain, helix–loop–helix structures
and a NEMO-binding domain (NBD). The IκB proteins are
degraded by proteasome and NF-κB dimers enter the nucleus.
IκBβ plays a unique role in determining specific target gene
expression; it preferentially binds cRel-containing NF-κB dimers,
and these dimer combinations bind to specific DNA sequences
and selective downstream genes are targeted (Sen and Smale,
2010). Several different stimuli could trigger NF-κB signaling in
the CNS, including cytokines (tumor necrosis factor κ (TNFα)
and IL-(1), chemokines, virus as well as injury or oxidative
stress. In some cases stimuli are specific for a cell type.NF-
κB is activated by stimuli specific of the CNS like neural cell
adhesion molecule (N-CAM; Krushel et al., 1999), neurotrophins
(NGF and S100ββ; Carter et al., 1996) or amyloid β (Aβ) peptide
(Behl et al., 1994). NF-κB enables the transcription of the genes
encoding many pro-inflammatory cytokines and chemokines.
Since cells from Nemo-deficient mice do not exhibit NF-κB
activation by LPS or IL-1 (Rudolph et al., 2000), activation of NF-
κB responsive genes by the innate immune triggers depends on
NEMO and progresses through the canonical NF-κB signaling
pathway. The expression of inducible NO synthase (iNOS), that
mediates NO production, is regulated by NF-κB and STAT
transcription factors (Farlik et al., 2010). The targets of NF-κB-
dependent pro-inflammatory cytokines, such as TNFα, tend to
be receptors that in turn, activate NF-κB pathway. NF-κB is
critical to the propagation and elaboration of cytokine responses.
TNF-α plays an important role in both local and systemic
inflammation, and it is a powerful inducer of NF-κB. The
predominant pathway triggered by TLR signaling is the canonical
NF-κB pathway, where IKKβ-dependent phosphorylation of
IκBα or IκBβ results in their ubiquitination and degradation by
the proteasome (Kawai and Akira, 2007). The nuclear NF-κB
dimers bind to κB DNA sites and start a transcriptional program
that includes numerous effectors of the innate immune system.
In the alternative (or non-canonical) pathway, both p105 and
p100 contain C-terminal ankyrin repeats that function as IκB-like
proteins. The p100-RelB complex is activated by phosphorylation
of the C-terminal region of p100 by an IKKα–IKKα homodimer
(lacking IKKβ and NEMO), which leads to ubiquitination and
further degradation of the p100 IkB-like C-terminal sequences
to generate a p52-RelB heterodimer (Sun, 2011). This pathway
is triggered by CD40, LT (lymphotoxin) β receptor and the
BAFF (B-cell-activating factor belonging to the TNF family)
receptor.
In either pathway, the unmasked NF-kB complex can
then enter the nucleus to activate target gene expression. In
the classical pathway, one of the target genes activated by
NF-κB is that which encodes IkBα. Newly-synthesized IkBα
can enter the nucleus, remove NF-κB from DNA, and export
the complex back to the cytoplasm to restore the original
latent state. Furthermore, IKKα-deficient mice show increased
production of pro-inflammatory chemokines and cytokine and
show increased inflammatory responses in local and systemic
inflammation (Lawrence et al., 2005; Li et al., 2005). The IKKα-
mediated repression of transcriptional responses influence the
level of nuclear p65 and c-Rel (Lawrence et al., 2005). Recent
reports have shown that IKKβ also influence anti-inflammatory
response in macrophages. IKKβ not only inhibits macrophage
function by interfering with the STAT pathway during infection
(Fong et al., 2008), but also suppresses the secretion of IL-1β
(Greten et al., 2007). In the CNS, NF-κB activation can be
negatively regulated by a several cytokines like IL-4, IL-10,
transforming growth factor β (TGFβ), and other molecules
like glycogen synthase kinase-3 (GSK-3β) and glucocorticoids
(Kaltschmidt et al., 2005). During neuro inflammation in
activated glial cells IL-4 inhibits NF-κB via a peroxisome
proliferator activated receptor (PPAR)-γ-mediated mechanism
and allows survival of differentiating oligodendrocyte precursors
(Paintlia et al., 2006). Other studies demonstrated that GSK-3β
negatively regulated NF-κB activity in astrocytes (Sanchez
et al., 2003). Moreover, it was reported that IL-4 and IL-10
that block IL-1β-induced NF-κB activation in astrocytes, also
diminished IL-1β-induced Akt phosphorylation (Pousset et al.,
2000).
CYSTATINS
Cystatin is a name derived from cysteine protease inhibitor.
They are reversible and tight-binding inhibitors of the papain
(C1) and legumain (C13) families of cysteine proteases
and have significant similarities in amino acid sequence
(Barrett, 1981; Barrett et al., 1986). The MEROPS database
(http://merops.sanger.ac.uk/) lists members of the cystatin family
(family I25, clan IH), distributed in protozoa, plants, fungi and
animals as well as in viruses (Rawlings et al., 2014). Initially,
they were characterized as inhibitors of endolysosomal cysteine
cathepsins, however recently some alternative functions for
cystatins were proposed. Endolysosomal proteases and their
inhibitors play an important role in the initiation and regulation
of immune response (Bird et al., 2009; Kopitar-Jerala, 2012).
On the basis of sequence homology, the presence or absence of
disulfide bonds and physiological localization, of three families
of cystatins were described: family I (stefins), family II (cystatins)
and family III (kininogens; Kopitar-Jerala, 2006; Turk et al.,
2008). Type 1 cystatins—stefins are mostly intracellular cystatins
present in the cytosol, mitochondria and the nuclei (Abrahamson
et al., 1986; Ceru et al., 2010; Maher et al., 2014a). Type 2 cystatins
are mainly extracellular, secreted proteins. They are synthesized
with 20–26 residue long signal peptides and most of them are
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found in physiologically relevant concentrations in body fluids
(Abrahamson et al., 1986; Kopitar-Jerala, 2006; Turk et al., 2008).
Type II cysatins possess also a second reactive site for inhibition
of the C13 family of cysteine proteases (legumain; Alvarez-
Fernandez et al., 1999). Cystatin C is expressed in a variety of
tissues and its expression and localization was associated with
various neurodegenerative pathologies like Alzheimer’s disease
(AD; Kaur and Levy, 2012). It associates with Aβ and inhibits
Aβ oligomerization in vitro and in vivo (Mi et al., 2007). A
point mutation in the cystatin C gene is responsible for the
dominantly inherited icelandic type of amyloidosis, hereditary
cystatin C amyloid angiopathy (HCCAA; Olafsson and Grubb,
2000). The increased expression of cystatin C was observed
in response to different types of insults to the brain, such as
ischemia and epilepsy (Palm et al., 1995; Lukasiuk et al., 2002).
Another type II cystatin, cystatin F was found abundant in
the cells of the immune system: myeloid cells (macrophages
and dendritic cells) and the cells involved in target cell killing
(NK cells and cytotoxic T cells (CTLs; Halfon et al., 1998; Ni et al.,
1998; Obata-Onai et al., 2002). It is expressed as di-sulfide-linked
dimer (Cappello et al., 2004) and translocated to endolysosomes
where it regulates cathepsin activity. Cystain F transport to
endolysosomes depends on its N-linked glycosylation and it
was reported that the secreted dimeric cystatin F could be
internalized and activated by the mannose-6-phosphate receptor
system (Colbert et al., 2009). Cleavage of its N-terminal region
by cathepsin V leads to the monomerization and influence the
inhibitory properties (Maher et al., 2014b). After proteolytic
removal of its N-terminal part, cystatin F becomes a potent
inhibitor of cathepsin C with the potential to regulate pro-
granzyme processing and cell cytotoxicity (Hamilton et al.,
2008). In cytotoxic cells, cystatin F therefore appears as a
key regulator of granzyme processing and consequently cell
cytotoxicity. Cystatin D was reported to inhibit proliferation,
migration and invasion of carcinoma cells (Alvarez-Díaz et al.,
2009). In addition, it was shown that a proportion of cystatin
D is targeted to cell nucleus at specific transcriptionally active
chromatin sites (Ferrer-Mayorga et al., 2015). Type-3 cystatins
are high molecular weight (60–120 kDa) proteins and have three
repeated type 2-like cystatin domains (Salvesen et al., 1986).
Cystatins in immune cells have been reported to participate in
the release of NO, phagocytosis and expression of cytokines
(Kopitar-Jerala, 2006; Magister and Kos, 2013; Maher et al.,
2014a). Stefin B belongs to the type one cystatins and is located
in the cytosol, mitochondria and nucleus (Ceru et al., 2010;
Maher et al., 2014a). Mutations in the gene encoding stefin B
are present in patients with a form of progressive myoclonus
epilepsy of Unverricht-Lundborg type (EPM1; Pennacchio et al.,
1996, 1998; Lalioti et al., 1997a,b). EPM1 is an autosomal
recessively inherited neurodegenerative disease, characterized
by the cerebellar granule neurons apoptosis, progressive ataxia
and myoclonic epilepsy (Pennacchio et al., 1996; Joensuu et al.,
2008). In lymphoid cells of EPM1 patients, increased cathepsin
activity, due to reduced expression of stefin B was reported
(Rinne et al., 2002), we determined increased overall cathepsin
activity in untreated, as well as in classically activated stefin
B-deficient BMDMs compared to wild type cells (Maher et al.,
2014c). We showed that in the nucleus stefin B interacts with
cathepsin L and nucleosomes, specifically with histones H2A.Z,
H2B, and H3 (Ceru et al., 2010). Goulet et al. (2004) has shown
that only shorter procathepsin L isoforms translocate to the
nucleus and stimulate processing of the CUX1 transcription
factor at the G1/S transition of the cell cycle. The delay in
cell cycle progression in cells overexpressing stefin B was
associated with the inhibition of cathepsin L in the nucleus,
confirmed by decreased cleavage of the CUX1 transcription
factor (Ceru et al., 2010). In addition, we have shown that
stefin B overexpression in the nucleus of astrocytoma cells
T89G delayed not only cell cycle progression, but also caspase
activation (Sun et al., 2012). A recent work demonstrated that
the early microglial activation precedes neuronal loss in the
brain of the stefin B deficient mice (Tegelberg et al., 2012). In
our recent work we showed that stefin B-deficient mice were
significantly more sensitive to the lethal LPS-induced sepsis
due to increased caspase-11 expression (Maher et al., 2014a).
The increased caspase-11 gene expression and better caspase-
1 and -11 processing determined in stefin B deficient bone
marrow-derived macrophages (BMDMs) resulted in enhanced
IL-1β and IL-18 processing and secretion (Figure 1). Upon LPS
stimulation, stefin B was targeted into the mitochondria, and
the lack of stefin B resulted in the increased destabilization
of mitochondrial membrane potential and mitochondrial ROS
generation. We have determined increased NF-κB signaling in
stefin B deficient BMDMS upon LPS stimulation, in reverse
experiment when stefin B was over-expressed in macrophage
reporter cell line RAW-blue, a decreased NF-κB activation was
determined upon LPS stimulation (Maher et al., 2014a). The
expression of caspase-11 is regulated by NF-κB and STAT-1
transcription factors (Schauvliege et al., 2002). Since STAT-1
signaling is downregulated in stefin B deficient BMDMs upon
LPS stimulation. We propose that stefin B could modulate the
caspase-11 gene expression in an NF-κB-dependent manner.
Okuneva et al. (2015) reported significantly higher stefin B
mRNA expression in microglia than in neurons or astrocytes,
which is in line with our observation that stefin B is highly
upregulated in activated macrophages (Maher et al., 2014c).
In stefin B-deficient macrophages we detected increased LPS-
induced pro-inflammatory NO production, but decreased IL-10
expression (Maher et al., 2014c). The phosphorylation of ERK
and JNK MAP-kinases were significantly decreased in stefin B-
deficient macrophages, as well as STAT-3 phosphorylation. The
results in macrophages could be compared to the signaling events
in microglia. Activation of cocultures of microglial and astroglial
cells with LPS strongly induces IL-10 mRNA expression, IL-10
production and release (Ledeboer et al., 2002).
Among type II cystatins, the most abundant cystatin is
cystatin C. It was described first as a ‘‘post-γ-globulin’’ or
‘‘γ-trace’’ (Grubb and Löfberg, 1982). It is expressed in various
tissues and mostly secreted from the cells (Abrahamson et al.,
1986). In the CNS, cystatin C is secreted from the choroid plexus
into the cerebrospinal fluid. Various studies showed that cystain
C has a neuroprotective role in neurodegenerative diseases (Mi
et al., 2007; Kaur and Levy, 2012). Frendéus et al. (2009) reported
that mouse peritoneal macrophages lacking cystatin C expressed
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higher levels of IL-10 mRNA but lower TNF-α upon IFN-γ
stimulation, compared to similarly primed wild type cells. The
cystatin C-deficient macrophages also have reduced NF-κB p65
activation, compared to control cells. The precise mechanism
by which cystatin C influence increased IL-10 expression is still
elusive. Electrophoretic mobility shift analysis of nuclear extracts
from macrophages and showed that IL-10 suppressed nuclear
localization of NF-κB (Lentsch et al., 1997). Increased IL-10
expression could suppers NF-κB activation in cystatin C deficient
cells.
CONCLUSIONS
The precise mechanism by which type I cystatins, like stefin
B and type II cystatins cystatin C influence is still not
clear. The type one cystatins, stefins A and B are localized
to the cytoplasm and nucleus, while type II cystatins are
predominately secreted. In addition, upon LPS stimulation
stefin B is targeted to mitochondria and prevents excessive
mitochondrial ROS formation. The lack of stefin B resulted
in increased mitochondrial ROS formation and an increased
NF-κB activation, as well as the expression of NF-κB target
genes. Increased expression of stefin B in macrophages resulted
in diminished NF-κB signaling, while exogenous addition of
cystatin C to macrophages enhanced NF-κB p65 activity and
NF-κB target genes expression. Further experiments on cell
cultures as well as on mouse models could help us to elucidate the
precise mechanism by which cystatins influence NF-κB signaling.
Better understanding of the role of cystatins in these signaling
pathways could lead also to the development of new therapies
and medications.
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